Revvity Income from Continuous Operations 2010-2024 | RVTY
Revvity annual/quarterly income from continuous operations history and growth rate from 2010 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
- Revvity income from continuous operations for the quarter ending September 30, 2024 was $0.093B, a 187.62% increase year-over-year.
- Revvity income from continuous operations for the twelve months ending September 30, 2024 was $0.258B, a 21% increase year-over-year.
- Revvity annual income from continuous operations for 2023 was $0.18B, a 64.99% decline from 2022.
- Revvity annual income from continuous operations for 2022 was $0.513B, a 42.36% decline from 2021.
- Revvity annual income from continuous operations for 2021 was $0.889B, a 41.05% increase from 2020.
| Revvity Annual Income from Continuous Operations (Millions of US $) |
|
|---|---|
| 2023 | $180 |
| 2022 | $513 |
| 2021 | $889 |
| 2020 | $631 |
| 2019 | $228 |
| 2018 | $237 |
| 2017 | $157 |
| 2016 | $216 |
| 2015 | $189 |
| 2014 | $130 |
| 2013 | $174 |
| 2012 | $71 |
| 2011 | $1 |
| 2010 | $139 |
| 2009 | $73 |
| Revvity Quarterly Income from Continuous Operations (Millions of US $) |
|
|---|---|
| 2024-09-30 | $93 |
| 2024-06-30 | $73 |
| 2024-03-31 | $29 |
| 2023-12-31 | $64 |
| 2023-09-30 | $32 |
| 2023-06-30 | $59 |
| 2023-03-31 | $25 |
| 2022-12-31 | $97 |
| 2022-09-30 | $70 |
| 2022-06-30 | $162 |
| 2022-03-31 | $184 |
| 2021-12-31 | $156 |
| 2021-09-30 | $108 |
| 2021-06-30 | $246 |
| 2021-03-31 | $379 |
| 2020-12-31 | $283 |
| 2020-09-30 | $177 |
| 2020-06-30 | $137 |
| 2020-03-31 | $34 |
| 2019-12-31 | $65 |
| 2019-09-30 | $59 |
| 2019-06-30 | $69 |
| 2019-03-31 | $35 |
| 2018-12-31 | $71 |
| 2018-09-30 | $75 |
| 2018-06-30 | $65 |
| 2018-03-31 | $26 |
| 2017-12-31 | $-38 |
| 2017-09-30 | $97 |
| 2017-06-30 | $63 |
| 2017-03-31 | $36 |
| 2016-12-31 | $62 |
| 2016-09-30 | $54 |
| 2016-06-30 | $58 |
| 2016-03-31 | $42 |
| 2015-12-31 | $45 |
| 2015-09-30 | $55 |
| 2015-06-30 | $49 |
| 2015-03-31 | $40 |
| 2014-12-31 | $0 |
| 2014-09-30 | $43 |
| 2014-06-30 | $52 |
| 2014-03-31 | $35 |
| 2013-12-31 | $74 |
| 2013-09-30 | $41 |
| 2013-06-30 | $27 |
| 2013-03-31 | $32 |
| 2012-12-31 | $-13 |
| 2012-09-30 | $29 |
| 2012-06-30 | $34 |
| 2012-03-31 | $22 |
| 2011-12-31 | $-83 |
| 2011-09-30 | $28 |
| 2011-06-30 | $29 |
| 2011-03-31 | $27 |
| 2010-12-31 | $46 |
| 2010-09-30 | $27 |
| 2010-06-30 | $47 |
| 2010-03-31 | $20 |
| 2009-12-31 | $22 |
| 2009-09-30 | $13 |
| 2009-06-30 | $23 |
| 2009-03-31 | $15 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $13.859B | $2.751B |
| Revvity Inc. provides products, services and solutions to the diagnostics, life sciences and applied services markets worldwide. Its operating segment includes Discovery & Analytical Solutions and Diagnostics. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Revvity Inc., formerly known as PerkinElmer Inc., is based in Waltham, Massachusetts. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $88.397B | 10.97 |
| Cencora (COR) | United States | $45.651B | 17.16 |
| Natera (NTRA) | United States | $23.104B | 0.00 |
| DiDi Global (DIDIY) | China | $21.969B | 0.00 |
| ICON (ICLR) | Ireland | $18.002B | 16.03 |
| Avantor (AVTR) | United States | $14.742B | 22.10 |
| Viatris (VTRS) | United States | $13.929B | 4.29 |
| BioMerieux (BMXMF) | France | $12.558B | 0.00 |
| CochLear (CHEOY) | Australia | $12.074B | 0.00 |
| Solventum (SOLV) | United States | $11.587B | 0.00 |
| Medpace Holdings (MEDP) | United States | $10.906B | 30.72 |
| Doximity (DOCS) | United States | $9.727B | 57.25 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $9.707B | 0.00 |
| Charles River Laboratories (CRL) | United States | $9.517B | 18.39 |
| HealthEquity (HQY) | United States | $8.694B | 43.62 |
| Sonic Healthcare (SKHHY) | Australia | $8.191B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $6.259B | 29.11 |
| Amplifon S.p.A (AMFPF) | Italy | $5.864B | 29.89 |
| Organon (OGN) | United States | $4.082B | 4.12 |
| Sotera Health (SHC) | United States | $3.713B | 19.86 |
| BrightSpring Health Services (BTSG) | United States | $2.990B | 63.59 |
| Surgery Partners (SGRY) | United States | $2.625B | 29.93 |
| Concentras Parent (CON) | United States | $2.513B | 0.00 |
| GeneDx Holdings (WGS) | United States | $2.455B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $2.277B | 0.00 |
| Ardent Health Partners (ARDT) | United States | $2.255B | 0.00 |
| Premier (PINC) | United States | $2.006B | 10.44 |
| PACS (PACS) | United States | $1.955B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.734B | 45.50 |
| Teladoc Health (TDOC) | United States | $1.699B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.658B | 0.00 |
| Progyny (PGNY) | United States | $1.597B | 32.34 |
| Establishment Labs Holdings (ESTA) | $1.282B | 0.00 | |
| CareDx (CDNA) | United States | $1.267B | 0.00 |
| Embecta (EMBC) | United States | $1.132B | 7.92 |
| Pediatrix Medical (MD) | United States | $1.068B | 10.45 |
| AMN Healthcare Services Inc (AMN) | United States | $1.023B | 6.93 |
| Agilon Health (AGL) | United States | $1.001B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.563B | 14.73 |
| SBC Medicals (SBC) | United States | $0.526B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.526B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.490B | 0.00 |
| DocGo (DCGO) | United States | $0.416B | 15.69 |
| Sonida Senior Living (SNDA) | United States | $0.409B | 0.00 |
| Enhabit (EHAB) | United States | $0.382B | 33.04 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.242B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.234B | 0.00 |
| MultiPlan (MPLN) | United States | $0.206B | 0.00 |
| LifeMD (LFMD) | United States | $0.205B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.197B | 0.00 |
| Beauty Health (SKIN) | United States | $0.192B | 0.00 |
| Biodesix (BDSX) | United States | $0.185B | 0.00 |
| Nutex Health (NUTX) | United States | $0.168B | 0.00 |
| So-Young (SY) | China | $0.104B | 17.70 |
| ModivCare (MODV) | United States | $0.094B | 5.09 |
| Ascend Wellness Holdings (AAWH) | United States | $0.092B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.072B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 1.61 |
| Singular Genomics Systems (OMIC) | United States | $0.049B | 0.00 |
| OncoCyte (OCX) | United States | $0.037B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.035B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.027B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.026B | 0.00 |
| Oncology Institute (TOI) | United States | $0.023B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.009B | 0.00 |
| KindlyMD (KDLY) | United States | $0.009B | 0.00 |
| XWELL (XWEL) | United States | $0.007B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.006B | 0.00 | |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |